StemRIM Inc. (4599) AI Stock Analysis

• Market Cap: ¥18.24B
• Dividend Yield: N/A
• Average Volume (3M): 122.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: 11.34%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -8.49
• Shares Outstanding: 62,681,200
• 10 Day Avg. Volume: 118,910
• 30 Day Avg. Volume: 122,863
• PEG Ratio: 1.85
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -30.8
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ¥288.00 ▲(12.94% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is mainly weighed down by weak recent financial performance (no revenue, large losses, and ongoing cash burn) and an unfavorable valuation signal (negative P/E with no dividend). Technicals are also soft, with the stock below key longer-term moving averages and negative MACD.

Positive Factors

Conservative balance sheet (no debt)

Near-zero debt reduces refinancing and interest-service risk, giving management flexibility to prioritize R&D or partner deals without immediate debt obligations. This conservatism improves survival odds through clinical timelines and lowers short-term financial shock vulnerability over 2–6 months.

Proven cash/revenue generation (2023)

A profitable 2023 with a sharp revenue jump and strong operating cash inflow shows the company can monetize programs or realize partner income. That track record indicates underlying assets or pathways to revenue, improving the chance of returning to positive cash generation when milestones are reached.

Lean organization

A headcount of 44 implies a relatively lean operating structure, which helps contain fixed costs and extend cash runway compared with larger peers. For a clinical-stage biotech, a smaller team supports agility in program execution and conserves cash between funding or partnership events.

Negative Factors

Zero revenue in 2024–2025

Reporting zero revenue in 2024–2025 removes margin support and indicates the company currently lacks sustainable commercial inflows. With no recurring revenue, the operating cost base produces losses that must be externally financed, structurally increasing financing dependency over the medium term.

Inconsistent cash generation / high burn

Cash flow volatility—strong inflow in 2023 but material outflows in multiple other years and significant burn in 2024–2025—creates runway uncertainty. This inconsistent generation increases the likelihood and frequency of external funding need, raising dilution and execution risk over the next several quarters.

Declining equity and dilution risk

Meaningful equity decline from 2021–2025 erodes the capital cushion and reflects persistent losses. Shrinking equity and negative returns raise the probability of future capital raises, which could dilute shareholders and constrain strategic optionality for trials or partnerships in the medium term.

StemRIM Inc. Business Overview & Revenue Model

Company Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

How the Company Makes Money

StemRIM Inc. generates revenue primarily through the development and commercialization of regenerative medicine therapies. This includes income from licensing agreements, research collaborations, and potential partnerships with pharmaceutical companies and research institutions. The company may also receive funding from grants and government research initiatives aimed at advancing regenerative medicine. Additionally, as its therapies advance through clinical trials, StemRIM could earn revenue from milestone payments and eventual product sales upon regulatory approval.

StemRIM Inc. Financial Statement Overview

Summary

Financials are pressured by zero revenue in 2024–2025 with very large operating/net losses and significant cash burn, despite a low-debt balance sheet. While the company has shown occasional strong years (notably 2023), the recent trend points to weakened sustainability and higher financing risk.

Income Statement

Profitability has been highly volatile and recently weak. After a profitable 2020 and 2023 (including a sharp revenue jump in 2023), the company reported zero revenue in 2024 and 2025 with very large operating and net losses, indicating a heavy cost base without offsetting commercial/partner income. Margins are not meaningful in the last two years due to the lack of revenue, and the earnings trajectory has turned decisively negative again.

Balance Sheet

The balance sheet is conservatively financed with essentially no debt across the period, which reduces financial risk. However, equity has declined meaningfully from 2021 to 2025, consistent with ongoing losses and cash burn. Returns on equity are negative in 2022, 2024, and 2025, reflecting value dilution risk if losses persist.

Cash Flow

Cash generation is inconsistent: operating and free cash flow were positive in 2020 and strongly positive in 2023, but turned materially negative in 2021, 2022, 2024, and 2025. The last two years show significant cash burn, broadly tracking net losses, which increases dependence on existing cash reserves or future funding. The sharp swing from 2023 inflows to 2024–2025 outflows highlights elevated volatility in funding/cash timing.

Breakdown	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	0.00	0.00	2.35B	22.98M	1.40B
Gross Profit	-49.50M	-44.35M	2.35B	22.98M	1.40B
EBITDA	-1.88B	-2.03B	218.05M	-1.90B	-532.23M
Net Income	-1.93B	-2.02B	168.35M	-1.95B	-582.45M
Balance Sheet
Total Assets	7.52B	9.08B	10.71B	9.60B	10.91B
Cash, Cash Equivalents and Short-Term Investments	6.99B	8.41B	10.22B	8.88B	10.17B
Total Debt	0.00	0.00	531.00K	3.67M	9.73M
Total Liabilities	204.43M	185.88M	336.02M	192.43M	212.64M
Stockholders Equity	7.31B	8.89B	10.37B	9.40B	10.70B
Cash Flow
Free Cash Flow	-1.46B	-1.88B	1.13B	-1.40B	-609.23M
Operating Cash Flow	-1.41B	-1.88B	1.14B	-1.40B	-519.65M
Investing Cash Flow	-42.50M	-4.78M	-344.00K	-330.00K	-92.72M
Financing Cash Flow	41.25M	78.97M	202.60M	112.86M	109.32M

StemRIM Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 255.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Positive. The current price of 255 is below the 20-day moving average (MA) of 293.75, below the 50-day MA of 283.42, and below the 200-day MA of 295.85, indicating a bullish trend. The MACD of 3.50 indicates Positive momentum. The RSI at 53.88 is Neutral, neither overbought nor oversold. The STOCH value of 32.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4599.

StemRIM Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥16.11B	-53.38	―	―	1.24%	-33.41%
4880	57 Neutral	¥8.07B	756.51	―	1.24%	-14.78%	-95.53%
7774	55 Neutral	¥27.57B	-61.60	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥12.14B	-10.84	―	―	-42.49%	-2.37%
4593	48 Neutral	¥48.74B	-16.08	―	―	-82.33%	47.73%
4599	43 Neutral	¥18.24B	-9.63	―	―	―	11.34%

StemRIM Inc. Corporate Events

StemRIM Wins Canadian Patent for Redasemtide Use in Cartilage Disorders

StemRIM Inc. has secured a forthcoming Canadian patent covering the use of its peptide drug candidate Redasemtide, an HMGB1 fragment peptide, as a therapeutic agent for a broad spectrum of cartilage disorders including osteoarthritis, meniscal damage, and certain forms of arthritis. The patent expands potential indications for Redasemtide in Canada and supports the company’s strategy to develop an intravenously administered, low-burden regenerative treatment that mobilizes mesenchymal stem cells to sites of cartilage injury, although StemRIM expects no material impact on its financial results for the fiscal year ending July 31, 2026.

By reinforcing Redasemtide’s intellectual property position in a key market, the move underpins StemRIM’s efforts to establish its regeneration-inducing platform in orthopedic and joint disease segments where current therapies are often limited and conditions are typically chronic and progressive. The additional protection may enhance the company’s competitive standing in cartilage repair therapies and provide long-term optionality for partnerships or future commercialization, while short-term financial effects remain minimal.

The most recent analyst rating on (JP:4599) stock is a Hold with a Yen281.00 price target. To see the full list of analyst forecasts on StemRIM Inc. stock, see the JP:4599 Stock Forecast page.

StemRIM Completes Global Phase 2b Enrollment for Stroke Drug Redasemtide

StemRIM Inc. announced that partner Shionogi & Co. has completed patient enrollment in a global Phase 2b clinical trial of Redasemtide (S‑005151), a peptide drug derived from StemRIM’s “Regeneration-Inducing Medicine” platform, for adults with acute ischemic stroke treated within 25 hours of onset. The trial, conducted across 18 countries including Japan, the U.S. and European states, is evaluating the efficacy and safety of Redasemtide versus placebo—with or without endovascular recanalization—using the 90-day modified Rankin Scale as the primary endpoint; the company noted the program is progressing as planned and is not expected to affect full-year earnings for the fiscal year ending July 2026, underscoring steady advancement of its lead regenerative therapeutic without near-term financial disruption.

StemRIM Secures Patent for Innovative Fatty Liver and NASH Therapy in Japan

StemRIM Inc. has announced the upcoming registration of a medical use patent for Redasemtide, its flagship regeneration-inducing drug candidate, specifically for treating fatty liver and non-alcoholic steatohepatitis (NASH) in Japan. With no existing drug treatments for these rising lifestyle-related conditions, this move could position StemRIM as a leader in addressing unmet medical needs while bolstering its market reputation within regenerative medicine.

StemRIM Inc. Reports Q3 2025 Financial Results Amid Ongoing R&D Investments

StemRIM Inc. reported its financial results for the three months ending October 31, 2025, showing a net loss, with no operating revenue recorded. The company continues to focus on the development of its regenerative medicine products, including Redasemtide, and anticipates significant cash outflows for research and development. Despite the financial challenges, StemRIM has secured sufficient funds for its R&D activities through 2028, indicating a strong commitment to its long-term development goals.

StemRIM Completes New Share Issuance for Stock Compensation

StemRIM Inc. has completed the issuance of new shares as restricted stock compensation, totaling 545,000 shares at an issue price of 278 yen per share, amounting to 151,510,000 yen. This strategic move is expected to enhance the company’s operational capabilities and strengthen its position in the biotech industry, potentially benefiting stakeholders by advancing its innovative regenerative medicine products.

StemRIM Inc. Forms Voluntary Compensation Committee to Enhance Governance

StemRIM Inc. has announced the establishment of a voluntary Compensation Committee to enhance transparency and effectiveness in determining the compensation of its directors and executive officers. This move is expected to provide an objective perspective on compensation matters, thereby strengthening the company’s governance structure and potentially improving stakeholder confidence.